Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic

NCT ID: NCT03463551

Last Updated: 2018-08-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-09-30
• Study Completion Date: 2020-03-31

Brief Summary

This study evaluates the safety and tolerability of 3 dose levels of ABL-101 and supplemental oxygen in acute stroke patients.

Detailed Description

Only a small proportion of patients are currently suitable for treatment with "clot busting" drugs after a stroke. Being able to visualise potentially rescuable brain tissue on scanning may allow more people to be treated. Currently available methods require extra time to acquire and are not therefore widely used. By carrying significant extra oxygen to the brain, the ABL-101 molecule may not only allow the visualisation of salvageable tissue, but also prevent progression of stroke damage in and have an additional direct benefit on tissue survival. Studies in animal models of stroke show smaller areas of stroke damage after ABL-101. There is therefore a rationale for testing this molecule in stroke patients, both as a diagnostic method, and also as a potential therapeutic agent.

Conditions

Acute Ischaemic Stroke

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

ABL-101 IV as per dosing cohort + Supplementary O2 for 24h

Patients will receive either ABL-101 or placebo (equivalent volume of 0.9% Sodium Chloride) within ascending dose groups of 6 patients each (4 to ABL-101, 2 to placebo).The starting cohort will be Cohort 1: 0.5mL/kg.

In the event that the start dose of Cohort 1 is considered intolerable in the opinion of the iDMC based on incidence of patients experiencing dose-limiting toxicities (DLTs), the iDMC will have the option of recommending a lower dose cohort (Cohort -1) of 0.25ml/kg (to a maximum of 25ml) be undertaken.

Cohort 1: 0.5 mL/kg to a maximum of 50ml; Cohort 2: 1.5mL/kg to a maximum of 150ml; Cohort 3: 3.0mL/kg to a maximum of 300ml.

All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration.

Group Type: EXPERIMENTAL

ABL-101

Intervention Type: DRUG

ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.

IV 0.9% NaCl as per dosing cohort + supplementary O2 for 24h

Cohort 1: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 2: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 3: Volume matched to the calculation used for ABL-101 using patient weight.

All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration.

Group Type: PLACEBO_COMPARATOR

0.9% NaCl

Intervention Type: OTHER

Placebo

Interventions

ABL-101

ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.

Intervention Type: DRUG

0.9% NaCl

Placebo

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Aged ≥18 years.
• Males or females not of child-bearing potential defined as being post-menopausal based on cessation of regular menses for a minimum of 12 consecutive months with no alternative cause, permanently sterilised (e.g. hysterectomy, bilateral tubal occlusion, bilateral salpingectomy), or having medically confirmed ovarian failure.
• Ischaemic stroke <72h after onset.
• Previous functional independence (estimated mRS <3).
• Capacity to consent.

Exclusion Criteria

• Women of child bearing potential.
• Contraindications to MRI scanning (eg cardiac pacemaker, ferromagnetic implants, known hypersensitivity to gadolinium containing contrast media).
• Known allergy to ABL-101 or any of its constituents, (including egg phospholipids).
• Clinical need for, or contraindication to, supplemental oxygen.
• Known impaired renal function (eGFR <30ml/min) precluding radiological contrast.
• Known thrombocytopaenia (platelet count <150x109) or history of platelet function disorder.
• Known intercurrent infection.
• Known severe COPD or cardiac failure (eg significantly limiting exercise capacity or requiring hospitalisation within the preceding 12 months).
• Known significant liver disease (eg liver failure or cirrhosis, chronic infectious or autoimmune hepatitis, or transaminases >3 times upper limit of normal).
• Any current medical condition causing impaired immunity (eg HIV infection, hyposplenism) or use of systemic immunosuppressant medication except for inhaled, nasal intra-articular or topical corticosteroids) on an ongoing basis or within the preceding 30 days.
• Any medical condition potentially limiting survival within the study follow-up period.
• Participation in another CTIMP within preceding 90 days.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Glasgow

OTHER

Sponsor Role: collaborator

Aurum Biosciences Ltd

UNKNOWN

Sponsor Role: collaborator

NHS Greater Glasgow and Clyde

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Keith Muir

Role: PRINCIPAL_INVESTIGATOR

University of Glasgow

Central Contacts

Maureen Travers

Role: CONTACT

Maureen.Travers@ggc.scot.nhs.uk

+44 1412321813

Alicia Murray

Role: CONTACT

Alicia.Murray@glasgow.ac.uk

Other Identifiers

GN16ST187

Identifier Type: -

Identifier Source: org_study_id